AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.
According to a new comprehensive report from The Insight Partners, the global biologics market is expected to reach U.S.$ ...
Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG are ...
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...
Bernstein has recently initiated AbbVie Inc (ABBV) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on June 5, 2024, HSBC Securities had raised the stock ...
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback